Cargando…

Piperacillin concentration in relation to therapeutic range in critically ill patients – a prospective observational study

BACKGROUND: Piperacillin levels after standard dosing have been shown frequently to be subtherapeutic, especially when renal clearance was augmented. Here, we aimed to determine if piperacillin was in its therapeutic range in a typically heterogeneous intensive care unit patient group, and also to d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zander, Johannes, Döbbeler, Gundula, Nagel, Dorothea, Maier, Barbara, Scharf, Christina, Huseyn-Zada, Mikayil, Jung, Jette, Frey, Lorenz, Vogeser, Michael, Zoller, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819271/ https://www.ncbi.nlm.nih.gov/pubmed/27039986 http://dx.doi.org/10.1186/s13054-016-1255-z

Ejemplares similares

Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study
por: Zoller, Michael, et al.
Publicado: (2014)

Therapeutic Drug Monitoring of Meropenem and Piperacillin in Critical Illness—Experience and Recommendations from One Year in Routine Clinical Practice
por: Scharf, Christina, et al.
Publicado: (2020)

Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study
por: Ehmann, Lisa, et al.
Publicado: (2017)

Systematic Evaluation of Voriconazole Pharmacokinetic Models without Pharmacogenetic Information for Bayesian Forecasting in Critically Ill Patients
por: Kallee, Simon, et al.
Publicado: (2022)

Towards model-informed precision dosing of piperacillin: multicenter systematic external evaluation of pharmacokinetic models in critically ill adults with a focus on Bayesian forecasting
por: Greppmair, Sebastian, et al.
Publicado: (2023)

Evaluation of the MeroRisk Calculator, A User-Friendly Tool to Predict the Risk of Meropenem Target Non-Attainment in Critically Ill Patients
por: Liebchen, Uwe, et al.
Publicado: (2021)

The higher the better? Defining the optimal beta-lactam target for critically ill patients to reach infection resolution and improve outcome
por: Scharf, Christina, et al.
Publicado: (2020)

The cytokine adsorber Cytosorb® does not reduce ammonia concentrations in critically ill patients with liver failure
por: Liebchen, Uwe, et al.
Publicado: (2023)

Pulmonary Penetration of Piperacillin and Tazobactam in Critically Ill Patients
por: Felton, T W, et al.
Publicado: (2014)

Development and evaluation of uncertainty quantifying machine learning models to predict piperacillin plasma concentrations in critically ill patients
por: Verhaeghe, Jarne, et al.
Publicado: (2022)

Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?
por: Udy, Andrew A, et al.
Publicado: (2015)

Comparison of Piperacillin and Tazobactam Pharmacokinetics in Critically Ill Patients with Trauma or with Burn
por: Selig, Daniel J., et al.
Publicado: (2022)

Myoclonic Jerks Secondary to Piperacillin and Nafcillin
por: Meyer, Michael A.
Publicado: (2014)

We need to optimize piperacillin-tazobactam dosing in critically ill patients—but how?
por: Cotta, Menino Osbert, et al.
Publicado: (2016)

Population Pharmacokinetics of Piperacillin in Non-Critically Ill Patients with Bacteremia Caused by Enterobacteriaceae
por: Merino-Bohórquez, Vicente, et al.
Publicado: (2021)

An Integral Pharmacokinetic Analysis of Piperacillin and Tazobactam in Plasma and Urine in Critically Ill Patients
por: Wallenburg, Eveline, et al.
Publicado: (2022)

Piperacillin/Tazobactam (ZOSYN)
por: Culver, Stephanie M., et al.
Publicado: (1996)

1414. Inoculum Effect of Piperacillin/Tazobactam Concentration on Emergence of Resistance in Klebsiella aerogenes
por: Custodio, Marco, et al.
Publicado: (2018)

The Role of Non-Enzymatic Degradation of Meropenem—Insights from the Bottle to the Body
por: Liebchen, Uwe, et al.
Publicado: (2021)

Mechanisms of Piperacillin/Tazobactam Nephrotoxicity: Piperacillin/Tazobactam-Induced Direct Tubular Damage in Mice
por: Yang, Jihyun, et al.
Publicado: (2023)

Individualization of Piperacillin Dosing for Critically Ill Patients: Dosing Software To Optimize Antimicrobial Therapy
por: Felton, T. W., et al.
Publicado: (2014)

Correction to: An Integral Pharmacokinetic Analysis of Piperacillin and Tazobactam in Plasma and Urine in Critically Ill Patients
por: Wallenburg, Eveline, et al.
Publicado: (2022)

The effect of meropenem versus piperacillin-tazobactam in critically ill patients with sepsis and septic shock()
por: Sun, Yang, et al.
Publicado: (2023)

Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam
por: Garneau, Julian R, et al.
Publicado: (2014)

Steady-State Piperacillin Concentrations in the Proximity of an Orthopedic Implant: A Microdialysis Porcine Study
por: Lilleøre, Johanne Gade, et al.
Publicado: (2023)

Piperacillin/tazobactam Induced Myelosuppression
por: Lee, Kirsty Wai Chung, et al.
Publicado: (2009)

Third generation cephalosporins and piperacillin/tazobactam have distinct impacts on the microbiota of critically ill patients
por: Gamage, Hasinika K. A. H., et al.
Publicado: (2021)

Population pharmacokinetics of piperacillin/tazobactam in critically ill Korean patients and the effects of extracorporeal membrane oxygenation
por: Kim, Yong Kyun, et al.
Publicado: (2022)

Personalized Piperacillin Dosing for the Critically Ill: A Retrospective Analysis of Clinical Experience with Dosing Software and Therapeutic Drug Monitoring to Optimize Antimicrobial Dosing
por: Chiriac, Ute, et al.
Publicado: (2021)

The effect of cytosorb® application on kidney recovery in critically ill patients with severe rhabdomyolysis: a propensity score matching analysis
por: Gräfe, Caroline, et al.
Publicado: (2023)

A Case of Piperacillin-induced Occupational Anaphylaxis: Detection of Serum IgE to Piperacillin-HSA Conjugate
por: Kim, Jeong-Eun, et al.
Publicado: (2011)

Effect of subinhibitory concentrations of imipenem and piperacillin on Pseudomonas aeruginosa toxA and exoS transcriptional expression
por: Haghi, F., et al.
Publicado: (2019)

DRESS syndrome induced by piperacillin-tazobactam
por: Sanchez-Gonzalez, Maria-Jose, et al.
Publicado: (2014)

Blood purification with a cytokine adsorber for the elimination of myoglobin in critically ill patients with severe rhabdomyolysis
por: Scharf, Christina, et al.
Publicado: (2021)

Continuous Infusion of Piperacillin/Tazobactam in Septic Critically Ill Patients—A Multicenter Propensity Matched Analysis
por: Gonçalves-Pereira, João, et al.
Publicado: (2012)

Evaluation of the risk of acute kidney injury with the use of piperacillin/tazobactam among adult critically ill patients
por: Saad, Mohamed O., et al.
Publicado: (2020)

60. Evaluation of Outcomes Associated with Intermittent Versus Extended Infusion of Piperacillin/tazobactam in Acutely Ill Veterans
por: Encarnacion, Marianne Angeli, et al.
Publicado: (2020)

Population Pharmacokinetic Model of Piperacillin in Critically Ill Patients and Describing Interethnic Variation Using External Validation
por: Sanches, Cristina, et al.
Publicado: (2022)

Systematic Evaluation of Pharmacokinetic Models for Model-Informed Precision Dosing of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy
por: Schatz, Lea Marie, et al.
Publicado: (2023)

No clinically relevant removal of meropenem by cytokine adsorber CytoSorb(®) in critically ill patients with sepsis or septic shock
por: Liebchen, Uwe, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mab43td0k4h78qqvc7b4dtk33m